Back2Sleep

Breathe freely at night, with no mask and no machine

The Back2Sleep nasopharyngeal tube is a soft device that keeps the airway open during sleep to reduce snoring and apneas in mild to moderate sleep apnea. A discreet approach, documented by clinical research.

See what the studies say →
😷

No mask

⚡

No machine
or electricity

🧳

Discreet & portable

🌙

Immediate
use

Breathe freely at night, with no mask and no machine Back2Sleep tube

How it works

A large share of snoring and apneas comes from collapse of the soft palate (the retropalatal area) during sleep. The nasopharyngeal tube acts right at this level.

Gentle insertion

Gentle insertion

A soft silicone tube is inserted through the nostril until it reaches past the area that becomes blocked behind the soft palate.

Airway support

Airway support

The tube “stents” the airway and stops the soft palate from falling backward.

Air and quiet restored

Air and quiet restored

Air flows freely: less vibration, so less snoring, and fewer apneas in suitable patients.

What the scientific studies say

Several hospital and university teams have evaluated Nastent, the original name of Back2Sleep. Here are the most notable results, in selected patients, with the conditions of each measurement.

Apneas 20.5 → 6.0

AHI measured under sedation

During a sedated endoscopy at Hôpital Foch, the AHI of 11 patients is 6.0 per hour with the tube, versus 20.5 at their diagnostic test. The authors consider a study during natural sleep necessary.

Tendron, Chabolle & Blumen, ENT Department, Hôpital Foch.
Snoring 10 / 11

Snoring gone

During the same endoscopy, snoring disappeared in 10 of 11 patients. Other studies on Nastent (Hirata, Furuie, Ohtsuka) also measure a reduction in snoring.

Tendron, Chabolle & Blumen, Hôpital Foch.
Mild to moderate sleep apnea 71

Lower severity and less snoring

Prospective study: the tube significantly reduces the AHI, desaturations and snoring volume.

Ohtsuka K. et al., Respiration, 2021.
Read the study (DOI)
Oxygenation 81.9 → 86.6%

Better oxygenation at night

After one month with the tube, minimum oxygen saturation rises and the respiratory event index falls from 22.4 to 15.7 per hour.

Okuno K. et al., Journal of Oral Rehabilitation, 2019.
Read the study (DOI)
Patient selection 57%

Responders with soft palate collapse

In 101 patients, 26% respond to treatment, and 57% when the obstruction is an anteroposterior collapse of the soft palate. The tube has no effect on the tongue base.

Dellweg A. et al., Journal of International Medical Research, 2022.
Read the study (DOI)
Tolerance 6.1 → 3.2

Discomfort that fades within a few days

In 14 volunteers, the discomfort index halves between day 4 and day 9 of use.

Furuie W. et al., Tokyo Medical and Dental University, poster, 2017.
See the poster (PDF)

Who it works best for

As the studies show, the nasopharyngeal tube is not a universal solution. It works mainly when the obstruction is at the level of the soft palate. A medical assessment helps identify the right candidates.

✓ Favorable indications

  • ✓ Bothersome simple snoring
  • ✓ Mild to moderate sleep apnea
  • ✓ Obstruction located at the soft palate
  • ✓ Patients who do not tolerate or who refuse CPAP
  • ✓ Need for a portable solution
Back2Sleep tube

× Less suitable

  • × Severe sleep apnea
  • × Tongue-base or multilevel obstruction
  • × Concentric collapse, large tonsils
  • × Complete bilateral nasal obstruction
ⓘ In the studies, 11% to 30% of patients did not tolerate the tube. Discomfort is common in the first nights and usually fades within a few days. Ask your doctor for advice before first use.

The publications at a glance

The studies published on Nastent, then a few papers on other nasopharyngeal stents.

Study Population Main result Access
Tendron, Chabolle, Blumen (Hôpital Foch, Paris) 11 patients (snoring + mild/moderate sleep apnea) AHI 20.5 → 6.0 under sedation, snoring gone in 10/11 Poster (PDF)
Okuno et al., 2019 30 patients (sleep apnea) REI 22.4 → 15.7, min. SpO₂ 81.9 → 86.6% DOI
Ohtsuka et al., 2021 71 patients (mild/moderate) ↓ AHI, snoring, desaturations. Effect maintained at 1 month DOI
Hirata & Satoh, 2015 6 patients (pilot) Good tolerance, snoring improved in all DOI
Dellweg, Kampmann, Tschopp, 2022 122 patients (101 analyzed) Responders: 26%, 57% in anteroposterior soft palate collapse. Hard to tolerate DOI, open access
Furuie et al., Tokyo Medical & Dental Univ. 16 volunteers without sleep apnea (9 snorers) Discomfort down within a few days, snoring index 0.260 → 0.040 Poster (PDF)
Traxdorf et al., 2016 (AlaxoStent, another device) 8 patients (vs CPAP) AHI 31.1 → 19.0 (CPAP: 8.2) DOI
Yenigun et al., 2020 (another device) 5 patients (feasibility) Stent placed under endoscopy with sedation: feasibility of soft palate support DOI
Kumar et al., 2015 (meta-analysis, nasopharyngeal airways) up to 193 patients AHI 44.1 → 22.7, min oxygenation 66.5 → 75.5% DOI
Victores et al., 2017 (standard nasopharyngeal tube) 41 patients Aid to surgical planning (DISE) DOI

ⓘ Sources: articles in scientific journals (DOI links) and two congress posters. AHI = apnea-hypopnea index. Some publications are open access, others require a subscription to the publisher.

Important information.

Back2Sleep is a medical device intended for the management of snoring and mild to moderate obstructive sleep apnea. The results shown come from clinical studies in selected patients, often with small sample sizes. They are not indicative of individual results.

A medical device is a regulated health product and, as such, carries the CE marking. Read the instructions for use carefully and ask a healthcare professional for advice.

Sleep apnea is a condition that requires medical diagnosis and follow-up. This device does not replace medical advice or, where relevant, continuous positive airway pressure (CPAP) treatment.

Back2Sleep is the manufacturer of the Class I medical device of the same name. Its registration can be viewed in the European database EUDAMED.

CE